Respimat®

Boehringer Ingelheim announced new data analyses from the pivotal Phase III TONADO® 1&2 studies (NCT01431274/NCT01431287)

In patients with no prior maintenance treatment, tiotropium/olodaterol Respimat® more than doubled the improvement in lung function* compared to Spiriva®…

9 years ago